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1. INTRODUCTION {#cas13524-sec-0001}
===============

Lung cancer is one of the leading causes of cancer related death in the world.[1](#cas13524-bib-0001){ref-type="ref"} The two major forms of lung cancer are non‐small‐cell lung cancer (NSCLC, approximately 85% of cases) and small‐cell lung cancer (SCLC, approximately 15% of cases).[2](#cas13524-bib-0002){ref-type="ref"} Even though several diagnostic techniques and treatments have been developed,[3](#cas13524-bib-0003){ref-type="ref"}, [4](#cas13524-bib-0004){ref-type="ref"} approximately 40% of NSCLC patients are first diagnosed at an advanced stage.[5](#cas13524-bib-0005){ref-type="ref"} The 5‐year overall survival (OS) rate of these patients was less than 18%.[6](#cas13524-bib-0006){ref-type="ref"}, [7](#cas13524-bib-0007){ref-type="ref"} Therefore, it is imperative to identify the relevant genes associated with the prognosis of NSCLC and provide individualization treatment.

Cell cycle‐related and expression‐elevated protein in tumor (*CREPT*) (GenBank [NM_021215](NM_021215)), a novel gene also called *RPRD1B* or *C20ORF77*, is involved in the development and prognosis of various tumors, including liver cancer, breast cancer, retroperitoneal leiomyosarcoma, and endometrial cancer.[8](#cas13524-bib-0008){ref-type="ref"}, [9](#cas13524-bib-0009){ref-type="ref"}, [10](#cas13524-bib-0010){ref-type="ref"}, [11](#cas13524-bib-0011){ref-type="ref"}, [12](#cas13524-bib-0012){ref-type="ref"} Lu et al[10](#cas13524-bib-0010){ref-type="ref"} have shown that *CREPT* enhances the expression of CyclinD1 by promoting the formation of a chromatin loop, by interacting with RNA polymerase II. Previous studies have shown that CREPT expression is correlated with tumor differentiation, Dukes' stage, and metastasis in colorectal tumors.[12](#cas13524-bib-0012){ref-type="ref"} She et al[13](#cas13524-bib-0013){ref-type="ref"} found that CREPT is elevated in retroperitoneal leiomyosarcoma tissues and plays important roles in the progression of retroperitoneal leiomyosarcoma. In our previous study, CREPT silencing significantly inhibited the proliferation and migration of NSCLC cell lines.[8](#cas13524-bib-0008){ref-type="ref"} However, the relationship between overexpression of CREPT and prognosis in NSCLC remains unknown. In this study, the expression of CREPT in 271 NSCLC tissues and corresponding adjacent non‐tumor tissues was detected by immunohistochemical staining, and the correlation between CREPT expression and clinicopathologic features were analyzed. Furthermore, CREPT was overexpressed in Calu‐1 cells and its biological function was investigated both in vitro and in vivo.

2. MATERIALS AND METHODS {#cas13524-sec-0002}
========================

2.1. Patients and tissue samples {#cas13524-sec-0003}
--------------------------------

We analyzed 271 NSCLC patients who underwent complete tumor resection with mediastinal lymph node dissection in the Department of Thoracic Surgery, Tangdu Hospital (Xi\'an, China) from 2006 to 2010.[1](#cas13524-bib-0001){ref-type="ref"}, [14](#cas13524-bib-0014){ref-type="ref"} Surgically excised NSCLC tissue samples with matched adjacent non‐cancer lung tissues were embedded in paraffin. Thirty‐five freshly collected paired NSCLC tissues of these samples were stored in liquid nitrogen for further study. Adjacent non‐cancer tissue samples were collected from the same patients and histologically identified to be collagen tissue and bronchial epithelial cells. Patients who received preoperative chemotherapy and radiotherapy were excluded from this study. Clinical information was obtained from the medical records of the enrolled patients. The follow‐up was obtained by telephone interviews to 2014, with a median follow‐up period of 56 months for living patients. The evaluation of histologic classification and differentiation were carried out independently by two pathologists. All tumors were staged according to the pathological TNM classification of the UICC (7th edition). The study protocol was approved by the Regional Ethics Committee for Clinical Research of the Fourth Military Medical University (Xi\'an, China). Each patient provided written informed consent for use of their medical records and tissue specimens.

2.2. Cell culture {#cas13524-sec-0004}
-----------------

Human NSCLC cell lines (H520, A549, H838, Spc‐A‐1, and Calu‐1) were purchased from ATCC (Manassas, VA, USA). The cells were cultured in RPMI‐1640 (Gibco, USA) containing 10% FBS (Gibco) and 1% penicillin--streptomycin. Cells were cultured at 37°C in a humidified atmosphere of 5% CO~2~.

2.3. Immunohistochemistry {#cas13524-sec-0005}
-------------------------

The paraffin‐embedded tissues were sliced into 3‐μm sections and deparaffinized, then the slides were boiled in 10 mmol/L citrate buffer for antigen retrieval and blocked with 10% goat serum. The slides were then incubated with primary anti‐CREPT (1:200; GeneTex) or anti‐Ki‐67 (1:200; GeneTex) antibodies overnight. The same concentration of antigen‐specific antibody (Kangwei) was used as negative control. After washing with PBS, the tissue sections were incubated with EnVision HRP (Kangwei, China) as the secondary antibody. Finally, the DAB Elite kit (Zhongshan, China) was used for chemiluminescence analysis. All stained sections were examined by two independent investigators who were blinded to the clinical features and outcomes. The immunohistochemical (IHC) staining scores were based on the following criteria: (i) the percentage of positive cells (0, ≤5%; 1, 6%‐25%; 2, 26%‐50%; 3, 51%‐75%; and 4, \>75%); (ii) the staining intensity (0, no color; 1, yellow; 2, brown; and 3, tan); and (iii) the two grades were multiplied together and specimens were assigned to one of four levels: 0, negative (−); 1‐4, weakly positive (+); 5‐8, moderately positive (++); and 9‐12, strongly positive (+++).[8](#cas13524-bib-0008){ref-type="ref"}, [15](#cas13524-bib-0015){ref-type="ref"} To investigate the correlation of protein expression, (−) and (+) were considered as low expression, and (++) and (+++) were considered as high expression.

2.4. Western blot analysis {#cas13524-sec-0006}
--------------------------

Cells and tissue samples were harvested in lysis buffer containing protease inhibitor cocktail. Cell lysates were separated by SDS‐PAGE and transferred onto PVDF membrane. Then the membrane was blocked by 8% non‐fat milk before being incubated with specific antibodies overnight at 4°C (anti‐CREPT, 1:2000; anti‐Ki‐67, 1:3000; β‐actin, 1:2000). After washing with TBST, the membrane was incubated with a HRP‐conjugated secondary antibody (1:3000) at room temperature for 45 minutes. The visualized analysis was carried out using the Millipore chromogenic kit for Western blot analysis (Millipore, Billerica, MA, USA) and quantitatively analyzed using Quantity software (Bio‐Rad, USA).

2.5. Quantitative RT‐PCR {#cas13524-sec-0007}
------------------------

Total RNA from fresh tissues or cells was extracted using TRIzol reagent (Invitrogen, USA) and mRNA was reverse transcribed into cDNA synthesis with a reverse transcription kit (Thermo Fisher Scientific, USA) according to the manufacturer\'s instructions. The quantitative RT‐PCR (qRT‐PCR) was carried out using a CFX96 Real‐Time PCR system (Bio‐Rad) with SYBR Green reagents (TaKaRa, Japan). Gene expression was normalized to β‐actin. The primers used for real‐time PCR were: CREPT, 5′‐GCTGGAGAAGAAGCTCTCGG‐3′ (forward) and 5′‐ATTTGATTTGGCTTTGCGGAG‐3′ (reverse); and β‐actin, 5′‐TGGCACCCAGCACAATGAA‐3′ (forward) and 5′‐CTAAGTCATAGTCCGCCTAGAAGCA ‐3′ (reverse).

2.6. Plasmid transfection {#cas13524-sec-0008}
-------------------------

Plasmid pcDNA3.1 was constructed by PCR amplifying the *CREPT* gene, using primers 5′‐CGCGATATCATGTCCTCCTTCTCTGAGTC‐3′ (forward) and 5′‐CGCCTCGAGCTAGTCAGTTGAAAACAGGT‐3′ (reverse). The PCR products were the inserted between the *Eco*RV and *Xho*I sites in pcDNA3.1 to generate the recombinant plasmid, named pcDNA3.1‐CREPT. Electroporation was used to transfect pcDNA3.1‐CREPT and the empty vector into Calu‐1 cells according to the manufacturer\'s instructions. To generate stable CREPT overexpressing cell lines, cells were screened by 800 mg/mL G418 after transfection and cells stably expressing CREPT were maintained in medium with 400 mg/mL G418.

2.7. Cell proliferation assay {#cas13524-sec-0009}
-----------------------------

Cell proliferation was analyzed using CCK‐8 (Beyotime Institute of Biotechnology, Shanghai, China). Cells were cultured in 96‐well plates at a density of 2000 cells/well. Then CCK‐8 solution (10 μL) was added to each well and incubated at 37°C for 2 hours. The optical density of each well was measured at 450 nm and documented every 24 hours. The results were obtained from three independent experiments in triplicate. Growth curves were portrayed based on the optical density value.

2.8. Flow cytometry analysis {#cas13524-sec-0010}
----------------------------

Cell cycle progression was quantified using flow cytometry after propidium iodide staining. Cells were collected 48 hours after transfection, then fixed overnight with 70% ice‐cold ethanol and stained with 50 μg/mL propidium iodide (MP Biomedical, USA), and examined using a flow cytometer (FACScan; BD Biosciences, USA) at 488 nm. The results were analyzed by FlowJo 6.1 software.

2.9. Wound healing assay {#cas13524-sec-0011}
------------------------

Cell migration was assessed by a wound healing assay. Briefly, cells (5 × 10^5^ cells/well) stably transfected with CREPT or empty vector were selected using G418 and then cultured in 6‐well plates until confluent. The cell monolayer was scraped in a straight line and washed with PBS, and then images were captured at 0, 12, and 24 hours under a 10× objective (Olympus, Japan). The migration distance was measured and assessed using ImageJ software at six random optical fields on each filter to evaluate cell migration. The percentage change in migration was determined by comparison of the differences in wound width. The experiments were carried out in duplicate.

2.10. Transwell migration and invasion assay {#cas13524-sec-0012}
--------------------------------------------

The invasion and migration ability of the cells were examined using Transwell assay with a 24‐well Transwell chamber (8‐μm pore size; Corning Life Sciences, USA) according to the manufacturer\'s instructions. A total of 1 × 10^5^ serum pre‐starved cells in 400 μL media supplemented were plated in the upper chamber and the bottom chamber contained 600 μL RPMI‐1640 supplemented with 10% FBS. After incubation at 37°C for 48 hours, the non‐migration cells on the top surface of the membrane were completely removed. Meanwhile, the migrated cells on the bottom surface were fixed in dehydrated alcohol for 30 minutes and stained with crystal violet. Cells were counted from five random fields at 400× magnification. Cell invasion assay was carried out in the same conditions except the upper chamber was coated with Matrigel (BD Biosciences).

2.11. In vivo mouse models {#cas13524-sec-0013}
--------------------------

All experimental procedures were approved by the Animal Ethics Committee of the Fourth Military Medical University. Nude mice were randomly divided into Calu‐1/pcDNA3.1‐CREPT and Calu‐1/pcDNA3.1 groups. Calu‐1 cells (5 × 10^6^ cells in 0.2 mL PBS) stably transfected with CREPT or empty vector were injected s.c. into 6‐week‐old male BALB/c nude mice. Tumor volume was calculated according to the following formula: tumor volume (mm^3^) = (short diameter)^2^ × (long diameter) / 2. Tumor volume was assessed every 5 days. The mice were killed and photographed after 30 days. The tumor tissues were removed and weighed. In addition, IHC staining was carried out to evaluate the expression of CREPT or Ki‐67 in xenograft tissues. Western blot and qRT‐PCR analyses were carried out to assess the expression of Ki‐67.

2.12. Statistical analysis {#cas13524-sec-0014}
--------------------------

Data are expressed as values of mean ± SD. Results were evaluated using the *t*‐test. Associations between two groups were evaluated using the *χ* ^2^‐test and Spearman\'s correlation analysis. Survival curves were examined using the Kaplan--Meier method, and the significance of the difference was evaluated using the log--rank test. Univariate and multivariate survival analyses were undertaken using the Cox hazard regression model. All analyses were carried out with [spss]{.smallcaps} 19.0 software (SPSS, Chicago, IL, USA). *P *\< .05 was considered to be statistically significant.

3. RESULTS {#cas13524-sec-0015}
==========

3.1. Overexpression of CREPT in NSCLC tissues and cell lines {#cas13524-sec-0016}
------------------------------------------------------------

To compare the expression of CREPT between NSCLC tumor tissues and adjacent non‐tumor tissues, we undertook IHC staining using 271 NSCLC samples and adjacent non‐tumor tissues. The staining intensity was scored on a scale of negative (−), weak (+), moderate (++), and strong (+++) (Figure [1](#cas13524-fig-0001){ref-type="fig"}A). The CREPT staining was mainly located in the nucleus and occasionally in cytoplasm. The CREPT was expressed in 262 of 271 (96.7%) NSCLC samples and 114 of 271 (42.1%) corresponding adjacent normal bronchial epithelia (Figure [1](#cas13524-fig-0001){ref-type="fig"}B). To confirm the CREPT mRNA and protein levels in NSCLC, 35 pairs of fresh NSCLC tissues and adjacent non‐cancerous lung tissues obtained from patients were used for Western blot analysis and qRT‐PCR. The results showed that higher levels of CREPT were expressed in cancer lesions than in adjacent regions (*P *\< .05; Figure [1](#cas13524-fig-0001){ref-type="fig"}D,E). Similarly, CREPT was positively expressed in NSCLC cell lines. The expression of CREPT at the mRNA and protein levels in Calu‐1 cells was the lowest among five NSCLC cell lines (Calu‐1, H520, A549, H838, and SPC‐A‐1) (Figure [1](#cas13524-fig-0001){ref-type="fig"}C). The Calu‐1 cell line was thus selected for CREPT overexpression experiments.

![Expression of cell cycle‐related and expression‐elevated protein in tumor (CREPT) in non‐small‐cell lung cancer (NSCLC) tissues and cell lines. A,B, Representative immunohistochemical staining of CREPT in NSCLC tissues (adenocarcinoma \[ADC\] and squamous cell carcinoma \[SCC\]) and adjacent non‐tumor lung tissues. C, Protein and mRNA levels of CREPT in different NSCLC cell lines. D,E, Western blot and quantitative RT‐PCR showed that the expression of CREPT in tumor tissue (T) was higher than that in paired adjacent non‐tumor lung tissues (N). Data shown as mean ± SD. \*\**P* \< .01](CAS-109-1012-g001){#cas13524-fig-0001}

3.2. Correlation between CREPT expression and clinicopathologic features {#cas13524-sec-0017}
------------------------------------------------------------------------

In order to determine the clinical significance of CREPT in NSCLC, the relationship between CREPT expression and clinicopathologic characteristics was investigated (Table [1](#cas13524-tbl-0001){ref-type="table-wrap"}). The CREPT expression was significantly associated with clinical stage (*P* = .025), tumor differentiation (*P* = .000), and lymphatic metastasis (*P* = .020). There was a strong correlation between CREPT expression and Ki‐67 proliferation index (*P* = .002). However, no significant relationship was observed between CREPT expression and age (*P* = .380), gender (*P* = .627), smoking history (*P = *.894), tumor size (*P* = .253), pathology (*P* = .638), or tumor location (*P* = .121).

###### 

Cell cycle‐related and expression‐elevated protein in tumor (CREPT) expression and clinicpathologic features in 271 patients with non‐small‐cell lung carcinoma

  Variable                Total   CREPT expression   *P*‐value              
  ----------------------- ------- ------------------ ----------- ----- ---- ---------------------------------------------
  Age, y                                                                    
  ≤61                     139     5                  31          87    16   .380
  \>61                    132     4                  23          89    16   
  Gender                                                                    
  Male                    204     8                  41          131   24   .627
  Female                  67      1                  13          45    8    
  Smoking history                                                           
  Yes                     173     7                  34          111   21   .894
  No                      98      2                  20          65    11   
  Tumor size, cm                                                            
  ≤5                      140     3                  34          85    18   .253
  \>5                     131     6                  20          91    14   
  Pathology                                                                 
  Adenocarcinoma          155     5                  30          110   19   .638
  Squamous carcinoma      116     4                  24          75    13   
  Clinical stage                                                            
  I                       69      2                  20          43    4    .025[a](#cas13524-note-0002){ref-type="fn"}
  II                      101     5                  25          55    16   
  III                     98      2                  9           75    12   
  IV                      3       0                  0           3     0    
  Tumor differentiation                                                     
  Well                    15      2                  11          2     0    .000[b](#cas13524-note-0003){ref-type="fn"}
  Moderate                185     7                  41          119   18   
  Poor                    71      0                  2           55    14   
  Lymphatic metastasis                                                      
  Yes                     150     7                  19          100   24   .003[b](#cas13524-note-0003){ref-type="fn"}
  No                      121     2                  35          76    8    
  Location                                                                  
  Central                 177     5                  38          111   23   .121
  Peripheral              94      4                  16          65    9    
  Ki67                                                                      
  Negative                12      2                  5           5     0    .002[b](#cas13524-note-0003){ref-type="fn"}
  Positive                259     7                  49          171   32   

*P *≤ .05.

*P* ≤ .01.
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### 3.2.1. Overexpression of CREPT promotes cell proliferation by inducing cells to enter G1 phase from S phase {#cas13524-sec-0018}

To investigate the role of CREPT on the progression of NSCLC, pcDNA3.1‐CREPT plasmid was adopted to transfect the Calu‐1 cell line and G418 screening to obtain stable cell lines highly expressing CREPT. We confirmed the efficacy of CREPT overexpression using Western blot analyses and qRT‐PCR (Figure [2](#cas13524-fig-0002){ref-type="fig"}A). To determine the impact of CREPT on regulating cell growth, CCK‐8 assay was undertaken and results showed that upregulation of CREPT expression in Calu‐1 cells dramatically promotes growth compared with the control group (Figure [2](#cas13524-fig-0002){ref-type="fig"}B). To further clarify the mechanism of the promotion effect of tumor cell growth by CREPT, we examined the cell cycle by flow cytometry. The results showed that upregulation of CREPT expression in Calu‐1 cells increased the proportion of cells in G1 phase compared with control cells (40.96 ± 3.21% vs 55.22 ± 4.12%), with concomitant decrease in S phase compared with control cells (33.42 ± 2.11% vs 21.8 ± 2.24%) (Figure [2](#cas13524-fig-0002){ref-type="fig"}C). These data strongly indicated that elevated CREPT levels in Calu‐1 cells markedly increased their proliferation through regulating the cell cycle.

![Cell cycle‐related and expression‐elevated protein in tumor (CREPT) overexpression promoted cell proliferation and accelerated the cell cycle in Calu‐1 non‐small‐cell lung cancer cells. A, mRNA and protein levels of CREPT in Calu‐1 cells after transfection of pcDNA3.1‐CREPT and pcDNA3.1 for 48 hours. B, Proliferation of CREPT overexpressed Calu‐1 cells was increased. C, Overexpression of CREPT resulted in G~1~ phase arrest in Calu‐1 cells (*\*P* \< .05, *\*\*P* \< .01)](CAS-109-1012-g002){#cas13524-fig-0002}

3.3. Facilitation of Calu‐1 cell migration and invasion in vitro by CREPT {#cas13524-sec-0019}
-------------------------------------------------------------------------

To further explore the potential biological function of CREPT in NSCLC progression, the migration and invasion capacities of CREPT in Calu‐1 cell were assessed using the scratch wound healing assay, Transwell migration assay, and Transwell invasion assay. The scratch wound healing assay showed that pcDNA3.1‐CREPT cells migrated a much longer distance into the wound area than the control cells (*P* \< .05; Figure [3](#cas13524-fig-0003){ref-type="fig"}A,B). Transwell migration assay further confirmed that overexpression of CREPT enhanced the migratory ability of Calu‐1 cells (*P* = .042; Figure [3](#cas13524-fig-0003){ref-type="fig"}C,D). In the Transwell invasion assay, more pcDNA3.1‐CREPT cells invaded into the lower chamber than pcDNA3.1 cells (Figure [3](#cas13524-fig-0003){ref-type="fig"}E). The quantitative analysis indicated that upregulation of CREPT expression dramatically promoted Calu‐1 cell invasion (*P* = .033, Figure [3](#cas13524-fig-0003){ref-type="fig"}F). These findings suggested that upregulation of CREPT expression in Calu‐1 cells enhances their migration and invasion abilities.

![Overexpression of cell cycle‐related and expression‐elevated protein in tumor (CREPT) promotes migration and invasion in Calu‐1 non‐small‐cell lung cancer cells. A, Representative images of wound healing assay for CREPT overexpressed Calu‐1 cells 12 hours and 24 hours after treatment. B, Statistical analysis indicates the overexpression of CREPT in Calu‐1 cells could significantly increase cell motility (*P* = .029). C, Representative images of Transwell migration assay for CREPT‐overexpressing Calu‐1 cells. D, Statistical analysis of the number of invasion cells between CREPT‐ overexpressing Calu‐1 cells and the control group (*P* = .039). E Representative images of Transwell invasion assay for CREPT‐overexpressing Calu‐1 cells and control cells. (F) Statistical analysis of the number of invasion cells between CREPT‐overexpressing Calu‐1 cells and the control group (*P* = .043). \**P* \< .05](CAS-109-1012-g003){#cas13524-fig-0003}

3.4. Overexpression of CREPT promotes tumor growth in vivo {#cas13524-sec-0020}
----------------------------------------------------------

We sought to probe whether overexpression of CREPT affects tumor growth, by using a Calu‐1 xenograft model. The same amount of Calu‐1/pcDNA3.1‐CREPT or Calu‐1/pcDNA3.1 cells was s.c. injected into nude mice. After 30 days, the CREPT overexpressing xenograft grew much faster than the control group (Figure [4](#cas13524-fig-0004){ref-type="fig"}A). The tumor volumes and weights in the pcDNA3.1‐CREPT group were clearly increased compared to the control group (Figure [4](#cas13524-fig-0004){ref-type="fig"}B,C). The expression of CREPT in the pcDNA3.1‐CREPT group was significantly higher than that in tumors treated with pcDNA3.1 (Figure [4](#cas13524-fig-0004){ref-type="fig"}D). To determine the effect of CREPT on proliferation, immunohistochemical staining showed that the proliferation marker Ki‐67 was stronger in the pcDNA3.1‐CREPT group (Figure [4](#cas13524-fig-0004){ref-type="fig"}D). In addition, the levels of Ki‐67 mRNA and protein in pcDNA3.1‐CREPT tumors were significantly higher than in the control group (Figure [4](#cas13524-fig-0004){ref-type="fig"}E). These results confirm that the overexpression of CREPT significantly promotes tumor growth in vivo.

![Overexpression of cell cycle‐related and expression‐elevated protein in tumor (CREPT) promotes non‐small‐cell lung tumor growth in vivo. A, Representative images of CREPT‐overexpressing and control Calu‐1 xenografts. B, Tumor volumes of CREPT‐overexpressing and control Calu‐1 xenografts. C, CREPT‐overexpressing Calu‐1 xenografts showed significantly increased tumor weight. D, Representative immunohistochemical staining of CREPT and Ki‐67 in xenograft tissues. E, The mRNA and protein expression level of Ki‐67 in xenograft tissues](CAS-109-1012-g004){#cas13524-fig-0004}

3.5. High levels of CREPT predict poor prognosis of NSCLC patients {#cas13524-sec-0021}
------------------------------------------------------------------

To explore the relationship between CREPT expression and survival of NSCLC patients, we analyzed the correlation between CREPT expression and clinical outcome in 271 NSCLC patients. Kaplan--Meier analysis showed that patients with higher CREPT expression revealed a significantly shorter OS (log--rank test, *P* = .01; Figure [5](#cas13524-fig-0005){ref-type="fig"}A) and RFS (*P* = .006; Figure [5](#cas13524-fig-0005){ref-type="fig"}B) compared to patients with lower CREPT expression.

![Cell cycle‐related and expression‐elevated protein in tumor (CREPT) overexpression predicts poor prognosis of patients with non‐small‐cell lung cancer. A,B, Patients with lower CREPT expression levels showed better overall survival (*P* = .01) (A) and better recurrence‐free survival (*P* = .006) (B). C,D, Kaplan--Meier survival analysis of adenocarcinoma patients (*P* = .30) (C) and squamous cell carcinoma patients (*P* = .03) (D), stratified by CREPT expression level. E,F, Kaplan--Meier survival analysis of pTNM I/II patients (*P* = .588) (E) and pTNM III/IV patients (*P* = .005) (F), stratified by CREPT expression level. (G,H) Kaplan--Meier survival analysis of lymph node‐negative patients (*P* = .01) (G) and lymph node‐positive patients (*P* = .03) (H), stratified by CREPT expression level. I,J, Kaplan--Meier survival analysis of patients with small tumor (diameter ≤5 cm, *P* = .70) (I) and large tumor (diameter \>5 cm, *P* = .002) (J), stratified by CREPT expression level](CAS-109-1012-g005){#cas13524-fig-0005}

In order to investigate the correlation of protein expression and patients' clinical outcomes, the median CREPT protein expression was used as the cut‐off point to divide high expression and low expression groups for NSCLC patients. In order to assess the relationship between CREPT expression and the clinical outcomes of NSCLC patients according to the different pathology, the patients were divided into the squamous cell carcinoma (SCC) and adenocarcinoma (ADC) groups. The median survival time of SCC patients with high CREPT expression was 31 months (95% confidence interval \[CI\], 21‐41 months) and low CREPT expression was 53 months (95% CI, 38‐68 months). The result showed that the group with high CREPT expression had a worse prognosis than those in the low CREPT expression group in SCC patients (*P* = .03; Figure [5](#cas13524-fig-0005){ref-type="fig"}). However, there were no obvious significant difference in the survival rate with respect to CREPT expression among ADC patients (*P* = .3; Figure [5](#cas13524-fig-0005){ref-type="fig"}C).

For further analysis, including clinical stages, we divided patients into early (pTNM I/II) stage and advanced stage (pTNM III/IV) to explore the influence of CREPT separately. As shown in Figure [5](#cas13524-fig-0005){ref-type="fig"}E, there was a barely detectable statistically significant trend in the survival rate with respect to CREPT expression (*P* = .588) in pTNM I/II patients. Nevertheless, the low CREPT expression group had a longer survival time compared to the high CREPT expression group in pTNM III/IV patients (*P* = .005; Figure [5](#cas13524-fig-0005){ref-type="fig"}F). Specifically, the median survival time of patients with high CREPT expression was 54 months (95% CI, 28‐80 months), whereas that of patients with low CREPT expression was 19 months (95% CI, 13‐25 months) in pTNM III/IV patients.

Considering the influence of lymph node metastasis on NSCLC patients' prognosis, we investigated the correlation between the expression of CREPT and prognosis in lymph node‐negative and lymph node‐positive patients. It was clear that patients with high CREPT expression had poor prognosis both in lymph node‐negative and lymph node‐positive patients (*P* = .01 and.03, respectively; Figure [5](#cas13524-fig-0005){ref-type="fig"}G,H).

In the further comparison, CREPT overexpression also correlated with the poor outcomes (*P* = .002; Figure [5](#cas13524-fig-0005){ref-type="fig"}J) in patients with large tumor size (diameter, \>5 cm). However, there were no statistical differences in the survival rate between high and low CREPT expression *(P* = .7; Figure [5](#cas13524-fig-0005){ref-type="fig"}I) in the patients with small tumors (diameter ≤5 cm).

To clarify whether CREPT expression represents a prognostic factor in patients with NSCLC, regression analysis using the Cox hazards model was carried out. Based on results of the univariate analysis, factors including CREPT expression, tumor size, lymphatic metastasis, pTNM stage, and tumor differentiation were all significantly associated with OS in NSCLC patients. However, age, gender, smoking history, pathology, and tumor location showed slight variation (all *P* \> .05). The data showed that, besides the TNM stage and tumor differentiation, CREPT expression was associated with poor survival of NSCLC patients (*P* \< .001; Table [2](#cas13524-tbl-0002){ref-type="table-wrap"}). These results indicated that CREPT might be an independent prognostic marker of NSCLC patients (hazard ratio \[HR\], 1.223; 95% CI, 1.043‐1.435; *P*  =  .013).

###### 

Cox proportional hazards model analysis of variables affecting survival in non‐small‐cell lung cancer patients

  Variable                                    Univariate analysis                             Multivariate analysis                                                 
  ------------------------------------------- ----------------------------------------------- ----------------------- --------------------------------------------- ---------------------
  CREPT expression, −/+/++/+++                \<.001[a](#cas13524-note-0004){ref-type="fn"}   1.302 (1.126‐1.506)     .013[a](#cas13524-note-0004){ref-type="fn"}   1.223 (1.043‐1.435)
  Age, ≤61/\>61 years                         .289                                            0.956 (0.879‐1.039)                                                   
  Gender, male/female                         .376                                            0.916 (0. 755‐1.112)                                                  
  Smoking, yes/no                             .114                                            0.870 (0.732‐1.034),                                                  
  Pathology, ADC/SCC                          .163                                            1.128 (0.952‐1.336)                                                   
  Location, central/peripheral                .644                                            1.042 (0.874‐1.242)                                                   
  Tumor size, ≤5 cm/\>5 cm                    \<.001[a](#cas13524-note-0004){ref-type="fn"}   1.138 (1.094‐1.185)     .066                                          1.043 (0.997‐1.090)
  Lymphatic metastasis, yes/no                \<.001[a](#cas13524-note-0004){ref-type="fn"}   1.838 (1.541‐2.192)     .126                                          0.839 (0.679‐1.035)
  TNM stage, I and II/III and IV              \<.001[a](#cas13524-note-0004){ref-type="fn"}   0.421 (0.355‐0.499)     .001[a](#cas13524-note-0004){ref-type="fn"}   0.480 (0.384‐0.599)
  Tumor differentiation, well/moderate/poor   \<.001[a](#cas13524-note-0004){ref-type="fn"}   1.602 (1.360‐1.887)     .109                                          1.163 (0.967‐1.400)

*P *≤ .05.

ADC, adenocarcinoma; CI, confidence interval; CREPT, cell cycle‐related and expression‐elevated protein in tumor; HR, hazard ratio; SCC, squamous carcinoma.
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4. DISCUSSION {#cas13524-sec-0022}
=============

In this study, we undertook IHC staining to evaluate CREPT expression in 271 NSCLC patients. Immunohistochemical evaluation showed that CREPT was expressed in 96.7% (262/271) NSCLC patients. We also detected the expression of CREPT by using qRT‐PCR and Western blot analysis in the expanded sample quantity. Compared with adjacent non‐tumor tissues, the mRNA and protein levels of CREPT were significantly elevated in NSCLC tissues. Elevated CREPT expression has been reported in 78.9% of retroperitoneal leiomyosarcoma patients and 77.8% of colorectal cancer patients.[12](#cas13524-bib-0012){ref-type="ref"}, [13](#cas13524-bib-0013){ref-type="ref"} We have further confirmed the elevated expression of CREPT mRNA and protein levels in NSCLC patients by expanding the clinical sample quantity. These findings implied it is easy to detect the expression of CREPT in NSCLC tumor tissues.

A previous study showed that CREPT is associated with clinical stage, lymph node metastasis, and distant metastasis in breast cancer patients.[9](#cas13524-bib-0009){ref-type="ref"} She et al. also revealed that the expression of CREPT may be closely related to histological grade in retroperitoneal leiomyosarcoma patients.[13](#cas13524-bib-0013){ref-type="ref"} The present study clearly indicated that CREPT expression is significantly correlated with clinical stage, tumor differentiation, and lymphatic metastasis in NSCLC patients. These results indicated that CREPT could play a significant role in NSCLC development and progression.

An earlier study showed that CREPT expression was correlated with poor prognosis in stomach cancer and retroperitoneal leiomyosarcoma patients.[10](#cas13524-bib-0010){ref-type="ref"}, [13](#cas13524-bib-0013){ref-type="ref"} Our previous study proved that CREPT overexpression was significantly correlated with shorter survival in colorectal cancer patients.[12](#cas13524-bib-0012){ref-type="ref"} In the current investigation, the survival analysis revealed that NSCLC patients with higher CREPT expression levels showed significantly shorter survival time compared to those with lower CREPT expression levels. Overexpression of CREPT was related to the malignant behavior of tumors during NSCLC progression. We also evaluated the prognostic significance of CREPT expression in different clinical features of NSCLC patients. Adenocarcinoma is associated with a poorer prognosis and a greater probability of distant recurrence compared with SCC.[16](#cas13524-bib-0016){ref-type="ref"} Gene expression profiles are known to differ substantially between ADC and SCC, and each histological subtype has a different etiology, carcinogenesis, and clinicopathologic behavior.[17](#cas13524-bib-0017){ref-type="ref"}, [18](#cas13524-bib-0018){ref-type="ref"}, [19](#cas13524-bib-0019){ref-type="ref"}, [20](#cas13524-bib-0020){ref-type="ref"} These studies revealed that the prognostic outcome might be different in SCC and ADC subgroups, which indicated that it is necessary to find an accurate prognostic marker. Based on our analysis, the expression level of CREPT is significantly associated with OS of SCC patients. Specifically, high CREPT expression was a much more significant survival factor for SCC patients than ADC patients. We speculated that CREPT is likely to represent a transformation factor associated with poor prognosis in the SCC development pathway. Considering the limitation of sample size, the differences in the role of CREPT carcinogenesis in SCC and ADC should be validated by further investigations.

We also investigated whether CREPT expression was associated with prognosis in NSCLC patients at different clinical stages. We noticed that the prognostic significance of CREPT expression was apparent in patients with advanced clinical stage, whereas the difference in the survival rate with respect to CREPT expression among patients with early stage was not significant. Further analysis suggested that lymph node metastasis patients with higher CREPT expression had a lower OS compared to those with lower CREPT expression; the difference was significant for lymph node‐negative patients as well as lymph node‐positive patients. A previous study has highlighted the size of the primary tumor as an independent prognostic factor for patients with NSCLC.[21](#cas13524-bib-0021){ref-type="ref"} Zhang et al. found that tumor size is an independent prognostic factor, for early stage as well as node‐positive and locally invasive disease.[22](#cas13524-bib-0022){ref-type="ref"} We detected that CREPT was a much more significant survival factor for NSCLC patients with larger tumor size (diameter \>5 cm) than those with smaller tumor size (diameter ≤5 cm). These findings suggested that the expression of CREPT was specifically more relevant to the survival of advanced staged SCC patients with large tumor size, which can be used as a precise prognostic marker for NSCLC patients.

In the univariate survival analysis, CREPT expression concomitant with TNM stages, tumor differentiation, and lymph node metastasis are all related with NSCLC patients' prognosis. More importantly, multivariate survival analysis revealed that CREPT expression (HR, 1.223; *P* = .013) was an independent prognostic factor, along with TNM stage (HR, 0.480; *P* = .001). We found that CREPT could serve as a potential independent biomarker to predict the prognosis of NSCLC patients.

In a previous study, we explored the biological effect of inhibiting CREPT on NSCLC cell proliferation in vitro.[8](#cas13524-bib-0008){ref-type="ref"} These results have motivated us to further investigate the critical role of CREPT in NSCLC cell proliferation. Therefore, we overexpressed CREPT in Calu‐1 cells and investigated its biological function both in vitro and in vivo. According to flow cytometric analysis, we found that upregulated CREPT expression can accelerate Calu‐1 cell proliferation by promoting the transformation of G~1~ phase to S phase. The CCK‐8 assay suggested that elevated CREPT expression markedly enhanced cell proliferation in Calu‐1 cells. Ki‐67 is recognized as a cell proliferation marker and strictly correlates with cell cycle progression.[11](#cas13524-bib-0011){ref-type="ref"} The IHC analysis showed that the expression of CREPT was significantly correlated with the Ki‐67 labelling index in NSCLC specimens. In addition, the tumor volumes and weights in the CREPT overexpression group were clearly increased compared to the control group. We detected the expression of Ki‐67 in xenograft by using IHC, Western blot analysis, and PCR. Compared to the control, much stronger expression of Ki‐67 was detected in xenograft at protein and mRNA levels. Wang et al. reported that overabundant CREPT promoted endometrial tumor growth through regulating the cell cycle.[23](#cas13524-bib-0023){ref-type="ref"} The pro‐proliferative role of CREPT was also verified both in vitro and in vivo.

The ability of cancer cells to undergo migration and invasion allows them to spread to lymph nodes and metastasize to distant organs. We undertook Transwell and scratch wound healing assays to investigate the function of CREPT in metastasis and invasion. Our results showed that overexpressed CREPT can promote metastasis and invasion in tumor. Our results provided new evidence supporting the involvement of CREPT in promoting the proliferation, migration, and invasion of NSCLC. Further studies are underway to elucidate the mechanisms underlying CREPT\'s regulation of NSCLC progression.

Taken together, our results reveal that CREPT was significantly upregulated in NSCLC compared with corresponding non‐tumor tissues. The expression level of CREPT was correlated with tumor differentiation, lymph node metastasis, and clinical stage. More importantly, CREPT overexpression level was associated with poor prognosis of patients. The survival analysis suggested that CREPT could serve as an independent predictor and potential target for NSCLC patients. Moreover, we showed that upregulated CREPT potently promoted NSCLC cell proliferation through regulation of the cell cycle in vitro and in vivo. The molecular mechanisms by which CREPT regulates the progression of tumor are the focus of our future studies.
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